Company profile: CellGate
1.1 - Company Overview
Company description
- Provider of anti-proliferative pharmaceutical products and cancer therapeutics, with applications in age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CellGate
OxSonics Therapeutics
HQ: United Kingdom
Website
- Description: Provider of a proprietary ultrasound-enabled drug delivery platform, SonoTran, designed to enhance penetration and distribution of anti-cancer agents within solid tumors. Offerings include SonoTran Particles with stabilised gas bubbles for cavitation, the SonoTran System for imaging, treatment and monitoring, a development pipeline with oncology drugs, and partnering services for pharmaceutical and biotech companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OxSonics Therapeutics company profile →
Wugen
HQ: United States
Website
- Description: Provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wugen company profile →
PMV Pharma
HQ: United States
Website
- Description: Provider of p53-targeted small molecule therapeutics for cancer, including the investigational candidate rezatapopt (PC14586) designed to reactivate the p53 Y220C mutation for advanced solid tumors. Offers drug discovery focused on restoring mutant p53 tumor suppressor function and conducts clinical trials to assess safety and efficacy in patients with specific p53 mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PMV Pharma company profile →
Shasqi
HQ: United States
Website
- Description: Provider of a click chemistry-based technology platform (CAPAC) that activates cancer drugs at the tumor site to minimize toxicity and improve outcomes; developer of SQ3370, a clinically validated asset that activates a doxorubicin protodrug with demonstrated safety and efficacy in advanced soft tissue sarcoma; offers antigen-targeting activators and protodrugs for payloads like monoclonal antibodies and traditional chemotherapy agents; in research collaboration with Johnson & Johnson.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shasqi company profile →
Crossbow Therapeutics
HQ: United States
Website
- Description: Provider of next-generation immunotherapies, including T-Bolt therapies that precisely target cancer cell antigens, and CBX-250, a T-cell engager for myeloid leukemia demonstrating potency and specificity in preclinical models.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crossbow Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CellGate
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CellGate
2.2 - Growth funds investing in similar companies to CellGate
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CellGate
4.2 - Public trading comparable groups for CellGate
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →